#South Korea #Seoul #Lunit #AI Pathology #ESMO

Overview of Lunit's Presentations at ESMO 2026

Lunit, a pioneering organization in AI-powered cancer diagnostics, is set to present five significant research studies at the European Society for Medical Oncology (ESMO) Congress 2026, occurring from October 23 to 27 in Madrid, Spain. These studies emphasize the critical role AI plays in pathology by analyzing cancer biomarkers and tumor microenvironments effectively across various cancer types.

Key Studies Overview

The studies that will be shared highlight the revolutionary potential of Lunit's AI-based platform, Lunit SCOPE. This platform utilizes advanced quantitative pathology analysis, allowing researchers to explore deep into cancer biomarker assessments and the unique characteristics of tumor tissues. The findings emerged from rigorous analysis of pathology images, revealing the biological and clinical significance inherent in tumor features.

Study Insights

Among the five studies, three prominently focus on AI applications in breast, lung, and pancreatic cancers:

1. Breast Cancer Study: This research is part of the AIforHER initiative, spearheaded by the Institut de Cancérologie de l'Ouest in France. Its objective is to enhance the accuracy of HER2 assessments in breast cancer using AI solutions. With HER2-targeted therapies now available to patients exhibiting lower levels of HER2 expression, this study evaluated multiple AI tools under consistent conditions to determine their effectiveness in classifying HER2 levels. At the ESMO conference, Lunit will report the findings from the first comparative evaluation, which sets the stage for deeper real-world assessments in subsequent studies.

2. Lung Cancer Study: A comprehensive Japanese study involving 993 patients diagnosed with non-small cell lung cancer (NSCLC) compared the PD-L1 tumor proportion scores evaluated by a traditional pathologist against those determined by Lunit's AI platform. The study revealed a notable concordance rate of 73%. However, interesting discrepancies were found, particularly in low PD-L1 expression cases, highlighting the possibilities and need for further clinical exploration into the efficacy of AI versus manual assessments.

3. Pancreatic Cancer Study: Researchers analyzed 181 patients with pancreatic ductal adenocarcinoma (PDAC) using the AI tool Lunit SCOPE IO to evaluate tumor-stroma ratios and endothelial cell proportions in pathology images. This analysis sought to correlate these features with KRAS mutation status and survival outcomes. The study realized that tumor-stroma ratios had different implications based on molecular subtypes, significantly affecting progression-free survival outcomes.

The Future of AI in Cancer Research

These studies represent just a fraction of how AI can transform cancer diagnostics. Brandon Suh, the CEO of Lunit, stated, “AI is helping researchers uncover new insights from pathology images across different cancer types. These studies reflect the diverse ways Lunit SCOPE can support cancer research.”

As Lunit continues to champion its mission to combat cancer with AI, the company plans to expand its collaborations and support ongoing research efforts that deepen our understanding of cancer biology and enhance precision oncology.

Conclusion

Lunit’s innovative research showcased at ESMO 2026 is a testament to the intersection of technology and healthcare, providing hope for more effective cancer diagnostics and treatments in the future. The ongoing evolution of AI in pathology signifies a move towards a new era where technology fosters breakthroughs in understanding and treating cancer.

Please note that Lunit SCOPE products are designated for research purposes only and are not intended for diagnostic applications.